Methods for the Treatment of Central Nervous System (CNS) Disorders and Mood Disorders

Title: Treatment for Depression and Other Mood Disorders

Invention: This technology is a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin Receptors. This modified version of SHU9119 can antagonize a Melanocortin 5 Receptor, allowing rapidly acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood disorders.

Background: Current treatments for depression include drugs with delayed therapeutic onset. This technology has the potential to alleviating depression and other mood disorders in a shorter time period.

Applications:

- Pharmaceutical compound for the treatment of depression, anxiety, and other mood disorders

Advantages:

- Targets specific receptor to minimize undesirable side effects.
- May achieve therapeutic effect in less time than alternative pharmacological interventions.
- Candidate for treating various mood disorders linked to anomalous Melanocortin receptor activation.

Licensing Manager:

Laura Silva
LauraS@tla.arizona.edu
(520) 626-1557

The University of Arizona, Tucson, Arizona
Inventors

Minying Cai
Research Professor, Chemistry and Biochemistry

Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry